Skip to main content

Advertisement

SpringerLink
Log in

Antimuscarinics for the treatment of overactive bladder: A review of central nervous system effects

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Antimuscarinic drugs commonly used to treat overactive bladder are often associated with central nervous system (CNS) side effects including cognitive dysfunction, memory impairment, dizziness, fatigue, and headache. New agents show reduced CNS penetrance and better selectivity for the M3 muscarinic receptor. However, changes associated with aging may lead to alterations in blood-brain barrier permeability. Therefore, use of antimuscarinics in the elderly or in patients with Alzheimer’s disease presents a significant challenge. This review highlights muscarinic receptor distribution and function in the CNS, provides a description and incidence of CNS side effects with therapy, offers information specific to currently available agents, and describes the use of antimuscarinics in special populations including children, the elderly, and patients with Alzheimer’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Abrams P, Cardozo L, Fall M, et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167–178.

    Article  PubMed  Google Scholar 

  2. Temml C, Heidler S, Ponholzer A, Madersbacher S: Prevalence of the overactive bladder syndrome by applying the International Continence Society definition. Eur Urol 2005, 48:622–627.

    Article  PubMed  Google Scholar 

  3. Stewart WF, Van Rooyen JB, Cundiff GW, et al.: Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20:327–336.

    PubMed  CAS  Google Scholar 

  4. Coyne KS, Zhou Z, Thompson C, Versi E: The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int 2003, 92:731–735.

    Article  PubMed  CAS  Google Scholar 

  5. Darkow T, Fontes CL, Williamson TE: Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005, 25:511–519.

    Article  PubMed  Google Scholar 

  6. Nabi G, Cody JD, Ellis G, et al.: Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006, CD003781.

  7. Sanctura (trospium chloride) 20 mg tablets prescribing information. Available at http://www.sanctura.com/pdf/sanctura_pi.pdf. Accessed February 1, 2007.

  8. Detrol LA tolterodine tartrate extended release capsules: prescribing information. Available at http://www.detrolla.com/cwpb/appmanager/detrolLA/detrolLADesktop?_nfpb=true&_pageLabel=detrolLA_prescribingInformation. Accessed February 1, 2007.

  9. Irwin DE, Milsom I, Hunskaar S, et al.: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006, 50:1306–1314, discussion 1314–1315.

    Article  PubMed  Google Scholar 

  10. Fick DM, Cooper JW, Wade WE, et al.: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003, 163:2716–2724.

    Article  PubMed  Google Scholar 

  11. Scarpero HM, Dmochowski RR: Muscarinic receptors: what we know. Curr Urol Rep 2003, 4:421–428.

    Article  PubMed  Google Scholar 

  12. Abrams P, Andersson KE, Buccafusco JJ, et al.: Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006, 148:565–578.

    Article  PubMed  CAS  Google Scholar 

  13. Yamada M, Miyakawa T, Duttaroy A, et al.: Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001, 410:207–212.

    Article  PubMed  CAS  Google Scholar 

  14. Haab F, Stewart L, Dwyer P: Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004, 45:420–429, discussion 429.

    Article  PubMed  CAS  Google Scholar 

  15. Garely AD, Kaufman JM, Sand PK, et al.: Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther 2006, 28:1935–1946.

    Article  PubMed  CAS  Google Scholar 

  16. Cardozo L, Lisec M, Millard R, et al.: Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004, 172:1919–1924.

    Article  PubMed  CAS  Google Scholar 

  17. Napier C, Gupta P: Darifenacin is selective for the human recombinant M3 receptor subtype [abstract 445]. Presented at the International Continence Society annual meeting. Heidelberg, Germany; August 28–30, 2002.

  18. Ikeda K, Kobayashi S, Suzuki M, et al.: M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002, 366:97–103.

    Article  PubMed  CAS  Google Scholar 

  19. Appell RA, Sand P, Dmochowski R, et al.: Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001, 76:358–363.

    Article  PubMed  CAS  Google Scholar 

  20. Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001, 57:414–421.

    Article  PubMed  Google Scholar 

  21. Kay G, Crook T, Rekeda L, et al.: Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006, 50:317–326.

    Article  PubMed  CAS  Google Scholar 

  22. Sugiyama T, Park YC, Kurita T: Oxybutynin disrupts learning and memory in the rat passive avoidance response. Urol Res 1999, 27:393–395.

    Article  PubMed  CAS  Google Scholar 

  23. Womack KB, Heilman KM: Tolterodine and memory: dry but forgetful. Arch Neurol 2003, 60:771–773.

    Article  PubMed  Google Scholar 

  24. Tanaka E: In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 1998, 23:247–255.

    Article  PubMed  CAS  Google Scholar 

  25. Gulsun M, Pinar M, Sabanci U: Psychotic disorder induced by oxybutynin: presentation of two cases. Clin Drug Investig 2006, 26:603–606.

    Article  PubMed  CAS  Google Scholar 

  26. Tsao JW, Heilman KM: Transient memory impairment and hallucinations associated with tolterodine use. N Engl J Med 2003, 349:2274–2275.

    Article  PubMed  CAS  Google Scholar 

  27. Partridge JG, Apparsundaram S, Gerhardt GA, et al.: Nicotinic acetylcholine receptors interact with dopamine in induction of striatal long-term depression. J Neurosci 2002, 22:2541–2549.

    PubMed  CAS  Google Scholar 

  28. Todorova A, Vonderheid-Guth B, Dimpfel W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001, 41:636–644.

    Article  PubMed  CAS  Google Scholar 

  29. Once-a-day Ditropan XL (oxybutynin chloride) extended-release tablets 5, 10, 15 mg. Full U.S. prescribing information. Available at http://www.ditropanxl.com/html/pdxl/prescribing_consumer.jsp;jsessionid=UYLZTKGIQK2EOCQPCCFTC0YKB2IIQNSC? Accessed February 1, 2007.

  30. Dmochowski RR, Nitti V, Staskin D, et al.: Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005, 23:263–270.

    Article  PubMed  CAS  Google Scholar 

  31. Enablex (darifenacin) extended release tablets: prescribing information. Available at http://www.enablex.com/info/tools/pi.jsp. Accessed February 1, 2007.

  32. VESIcare (solifenacin succinate) tablets. Available at http://www.astellas.us/docs/vesicare.pdf. Accessed February 1, 2007.

  33. Diefenback K, Donath F, Maurer A, et al.: Randomized, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in heathy young volunteers. Clin Drug Investig 2003, 23:395–404. Available at http://druginvestigation.adisonline.com.

    Article  Google Scholar 

  34. Ancelin ML, Artero S, Porter F, et al.: Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ 2006, 332:455–459.

    Article  PubMed  Google Scholar 

  35. Erdincler P, Tuzgen S, Erdincler UD, et al.: Influence of aging on blood-brain barrier permeability and free radical formation following experimental brain cold injury. Acta Neurochir (Wien) 2002, 144:195–199, discussion 199–200.

    Article  CAS  Google Scholar 

  36. Abdel-Rahman A, Shetty AK, Abou-Donia MB: Disruption of the blood-brain barrier and neuronal cell death in cingulate cortex, dentate gyrus, thalamus, and hypothalamus in a rat model of Gulf-War syndrome. Neurobiol Dis 2002, 10:306–326.

    Article  PubMed  CAS  Google Scholar 

  37. Sommer BR, O’Hara R, Askari N, et al.: The effect of oxybutynin treatment on cognition in children with diurnal incontinence. J Urol 2005, 173:2125–2127.

    Article  PubMed  CAS  Google Scholar 

  38. Blennow K, de Leon MJ, Zetterberg H: Alzheimer’s disease. Lancet 2006, 368:387–403.

    Article  PubMed  CAS  Google Scholar 

  39. Siegler EL, Reidenberg M: Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin Pharmacol Ther 2004, 75:484–488.

    Article  PubMed  CAS  Google Scholar 

  40. Perry EK, Kilford L, Lees AJ, et al.: Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol 2003, 54:235–238.

    Article  PubMed  CAS  Google Scholar 

  41. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, et al.: Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 2006, 24:516–524.

    Article  PubMed  CAS  Google Scholar 

  42. Jankowsky JL, Xu G, Fromholt D, et al.: Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol 2003, 62:1220–1227.

    PubMed  CAS  Google Scholar 

  43. Klausner AP, Fletcher S, Yang SK, et al.: Does oxybutynin alter amyloid beta peptides in a mouse model of Alzheimer’s Disease? [abstract]. J Urol 2005, 173:41.

    Google Scholar 

  44. Sharma S, Klausner AP, Fletcher S, et al.: The effect of oxybutynin on plaques, amyloid beta peptides, and behavior in mouse and human cybrid models of Alzheimer’s Disease [abstract]. J Urol 2006, 175:55.

    Google Scholar 

  45. Daniel JM, Hulst JL, Lee CD: Role of hippocampal M2 muscarinic receptors in the estrogen-induced enhancement of working memory. Neuroscience 2005, 132:57–64.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Virginia Commonwealth University School of Medicine, PO Box 980118, Richmond, VA, 23298, USA

    Adam P. Klausner

Authors
  1. Adam P. Klausner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William D. Steers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam P. Klausner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klausner, A.P., Steers, W.D. Antimuscarinics for the treatment of overactive bladder: A review of central nervous system effects. Curr Urol Rep 8, 441–447 (2007). https://doi.org/10.1007/s11934-007-0046-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-007-0046-0

Keywords

Search

Navigation